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progression of knee pain. The KOACAD system will be useful for objective
evaluation of the disease severity in daily clinical practice, just as bone
mineral density is in osteoporosis.
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Purpose: Pain is the most common, disabling symptom for people
with Osteoarthritis (OA). Cumulative data suggests dysfunctional pain
processing by the central nervous system, called central sensitization
(CS), contributes to pain in OA. CS can be associated with the neuro-
pathic pain (NP) symptom proﬁle including burning, electric-shock like
sensations, and sensitivity to light touch. Improved understanding of pain
mechanisms in OA, including development of “clinically feasible” tools to
identify individuals likely to have CS would facilitate development of novel
mechanism-based pain therapies. This ongoing study is assessing (1) NP
symptoms in subjects with symptomatic knee OA, using a NP question-
naire modiﬁed for use in OA, the modiﬁed painDETECT (mPD-Q), and the
Self-completed Leeds Assessment of Neuropathic Symptoms and Signs
pain scale (S-LANSS), which has been validated in other chronic pain
populations; (2) pain intensity, using the Von Korff Chronic Pain Grade
Scale (CPG) and, (3) co-morbid chronic pain and neurological conditions.
Methods: Eligible study subjects are members of an existing population-
based OA cohort with chronic symptomatic knee OA deﬁned by pain,
discomfort and/or stiffness in the knee(s) on most days for  3 months.
A standardized questionnaire was mailed to 268 cohort members to date,
to assess (1) pain quality for each knee using the mPD-Q, scored -1 to
38; and the S-LANSS, scored 0−24; (2) pain intensity, using the CPG,
scored 0–100; and (3) co-morbid conditions. Mean, median, and standard
deviation (SD) were evaluated for questionnaire scores. The proportion of
knee OA cohort participants with mPD-Q and S-LANSS scores in the ‘NP
range’ (mPD-Q score 19, S-LANSS score 12) was calculated using a
95% conﬁdence interval. Pearson correlations between mPD-Q and other
questionnaire scores (SLANSS and CPG) were examined.
Results: To date, 129 (48%) questionnaires have been returned. Thirty-
two (29%) responders reported no chronic knee pain. Among 92 (71%)
responders with chronic knee pain, 73 had chronic right and 63 had
chronic left knee pain. Mean (SD) mPD-Q scores were the same, 12 (7),
for right and left knees. Mean (SD) S-LANSS scores were 8 (8) for right
knees and 7 (7) for left knees. According to cut-points identiﬁed in other
pain populations, the proportion (95%CI) of study subjects with scores in
the ‘NP range’ on the mPD-Q was 0.21 (0.12−0.32) for right knees and
0.17 (0.08−0.28) for left knees; on the S-LANSS was 0.31 (0.20−0.42) for
the right knees and 0.25 (0.14−0.36) for left knees. The mPD-Q scores
had a moderate to high correlation with the S-LANSS scores for right
(r = 0.68) and left knees (r = 0.73). The mPD-Q scores had a moderate
correlation with CPG pain intensity scores for right (r = 0.61) and left
(r = 0.65) knees. The following factors did not explain the variability seen
in mPD-Q scores: presence of diabetes, another chronic pain condition,
a co-morbid neurological condition.
Conclusions: In a population-based cohort with chronic knee OA, almost
a quarter of subjects with painful knee OA scored in the ‘NP range’ on
both of the measures assessed. This subgroup of patients may beneﬁt
from further evaluation for NP likely due to CS and consideration of NP
medications. Further validation work on the mPD-Q is ongoing.
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Purpose: To further assess the construct validity of ICOAP, a new
osteoarthritis (OA) pain measure.
Methods: The new measure, ICOAP, is comprised of 5 items assessing
‘constant’ hip or knee pain and 6 items assessing ‘intermittent’ hip or
knee pain; item response options are on a 4-point scale from ‘not at all’
to ‘extremely’. Subscale and total scores are standardized to 0 to 100,
where higher scores indicate worse pain. The ICOAP was administered
by phone to an established community cohort aged 55+ years with
moderate to severe hip and/or knee OA. All subjects completed both
the hip and knee versions of the ICOAP, regardless of which joints were
painful at the time. Participants also completed other measures of arthritis
pain and disability (WOMAC pain, function and stiffness subscales;
McGill pain intensity scale, and the limitation dimension of the Late
Life Function and Disability Instrument), the Proﬁle of Mood States-Brief
(POMS) fatigue/inertia scale, the SF-36 general health perception scale,
the CES-D scale for depressed mood, the Lubben Social Network Scale,
and the Pain Catastrophizing Scale. Summary descriptive statistics were
calculated for all scale scores. Spearman’s rho correlation coefﬁcients
were calculated to assess the relationship between ICOAP Hip and Knee
subscale and total scores with each of the other measures. T-tests were
used to compare means ICOAP scores for men versus women.
Results: The mean age of the 659 participants was 77.6 years (58.7 to
97.9), 77.4% were female and 23.7% had < high school education; 631
had complete data for ICOAP Hip and 608 for ICOAP Knee. Mean score
(SD) for the hip was 26.8 (SD 25.0) and 18.0 (SD 26.8) for intermittent and
constant pain, respectively. For the knee, mean intermittent and constant
pain scores were 30.9 (SD 23.3) and 16.0 (SD 26.5), respectively. Women
had higher intermittent and total ICOAP pain scores than men (hip and
knee results similar, p< 0.05 for all). Within individuals, intermittent and
constant pain scores were only modestly correlated (r = 0.29 for the knee;
r = 0.46 for the hip, p< 0.0001 for both) and their strength of association
with other measures differed (e.g. correlation with pain catastrophizing
score: intermittent pain r = 0.27 versus constant pain r = 0.39). For the
hip, measures of coping, fatigue, mood and physical functioning were
more strongly related to constant than to intermittent pain. For the
knee, the reverse was generally true, with stronger correlations being
associated with intermittent knee pain scores. ICOAP score correlations
with WOMAC pain scores ranged from 0.39 (hips; ICOAP intermittent
pain) to 0.65 (knees; ICOAP total pain). Higher scores for both intermittent
and constant pain were associated with lower general health status,
higher scores on other pain and disability measures, higher scores for
depression, fatigue and pain catastrophizing, and lower scores for social
support.
Conclusions: Our results provide further evidence of the ICOAP as a
valid tool for evaluation of pain in hip and knee OA and supports use of
the two subscale scores for intermittent and constant pain independently
as distinct and important domains of OA pain.
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Purpose: Four previous studies (n = 1675) have shown that C-Reactive
Protein (CRP) levels are associated with (progression of) knee os-
teoarthritis (KOA). At this moment, there are only three studies (n = 968)
published, examining the relationship between CRP levels and joint
complaints or disability. In this population-based study, we analyzed the
association between CRP levels and KOA-related knee pain and the
relationship between CRP levels, body mass index (BMI) and KOA since
it is still not clear whether BMI plays a role as a confounder or as effect
mediator in this model.
Methods: In total, 1655 women from the Rotterdam Study had data
on radiographic knee OA, age, BMI and CRP levels. High-sensitivity
CRP measurements were performed using rate near-infrared particle
immunoassay. For all statistical analysis, log-transformed CRP values
were used. KOA was deﬁned as a Kellgren/Lawrence score 2 in one
or both knees. Knee pain was deﬁned as having pain in the right or left
knee during the last month or the past ﬁve years.
Results: Women with knee OA had 30% higher CRP levels compared
to women without KOA (p = 8×10−7), but after adjustment for age and
BMI this association disappeared (p = 0.3). We next stratiﬁed our data
according to BMI, to investigate the role of BMI as an effect modiﬁer. We
observed that women with a BMI< 27.0 kg/m2 and with KOA had 34%
higher levels of CRP compared to women without KOA (p = 0.004 after
adjustment for age and co-morbidity). Importantly, this association was
absent in women with a BMI> 27.0 kg/m2 (p = 0.63). CRP levels were
borderline signiﬁcant associated with an increased risk of knee pain in
our study (p = 0.053 after adjustment for age and BMI). This effect was
only visible in women with radiographic KOA (27% higher CRP levels,
p = 0.03 after adjustment for age and BMI) and not in women without
KOA (p = 0.43).
